BSG and neoplasm: As expected, tumor burden from the CD147+GPC3high HepG2 inoculated mice treated with GPC3-synNotch-inducible CD147-CAR-NK-92MI cells was reduced, compared with that of mice bearing CD147+GPC3low HepG2 tumor cells (Supplementary Fig. 16).